Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Air, Inc. (NASDAQ: XAIR) announced positive results from a pilot study evaluating the safety and efficacy of inhaled nitric oxide (NO) in patients hospitalized with community-acquired viral pneumonia, including COVID-19. The study, conducted in Israel, involved 40 participants and demonstrated that patients receiving inhaled NO experienced shorter durations of oxygen support and a trend toward reduced hospital stays compared to the control group. No treatment-related adverse events were reported, affirming the safety of inhaled NO as a potential therapeutic option.
Beyond Air, Inc. (NASDAQ: XAIR) announced its participation in three upcoming medical conferences to present new data on inhaled nitric oxide treatments. At the Pediatric Academic Societies 2022 Meeting, the company will share long-term safety data for high concentration inhaled nitric oxide in treating bronchiolitis on April 25. During the ECCMID 2022, new findings on COVID-19 treatment with a novel nitric oxide generator will be presented on April 23. Lastly, at ATS 2022, new results from the LungFit GO pilot study on high concentration inhaled nitric oxide in NTM will be discussed on May 17.
Beyond Cancer, an affiliate of Beyond Air (NASDAQ: XAIR), announced promising data on its gaseous nitric oxide (gNO) therapy for solid tumors. Presenting at the AACR Annual Meeting 2022, studies showed gNO induced immune cell recruitment and reduced suppressor cells, indicating a potential anti-tumor response. The in vivo study observed increased immune cells and reduced suppression in treated mice, while the in vitro results indicated a dose-dependent cytotoxic effect across several cancer cell lines. A first-in-human study is expected to begin in Q2 2022.
Beyond Air, a clinical-stage company specializing in nitric oxide therapies, announced two important presentations at the AACR Annual Meeting, set for April 8-13, 2022, in New Orleans. They will showcase research on nitric oxide's impact on cancer treatments, particularly a study demonstrating a single injection's ability to elicit an immune response in tumors and another analyzing its cytotoxic effects against various cancer cells. These advancements could change the landscape of therapies for respiratory conditions and solid tumors.
Beyond Air, Inc. (NASDAQ: XAIR) announced its financial results for Q3 FY2021, reporting no revenue compared to $0.1 million last year and a net loss of $8 million. They are progressing with the LungFit® PH PMA submission to the U.S. FDA, aiming for approval in H1 2022. The company raised $30 million for its oncology affiliate, Beyond Cancer, retaining 80% equity. Research and development expenses decreased, but general and administrative expenses rose to $4.9 million. Upcoming milestones include data presentations and patient enrollment for key clinical studies scheduled in 2022.
Beyond Air, a clinical-stage medical device and biopharmaceutical company, announced that its CEO, Steve Lisi, will participate in two investor conferences in March 2022. The first event is the 34th Annual Roth Conference from March 13-15, 2022 in Dana Point, California. The second is the Oppenheimer 32nd Annual Healthcare Conference, with a virtual presentation scheduled for March 16, 2022 at 10:00 AM ET. Beyond Air focuses on developing inhaled nitric oxide for respiratory conditions and ultra-high concentration nitric oxide for solid tumors.
Beyond Air, Inc. (NASDAQ: XAIR) has appointed Mr. David Dvorak and Dr. Gregory Berk to the Board of Directors of its affiliate, Beyond Cancer. Dvorak, with over 25 years in healthcare leadership, previously served as CEO of Zimmer Biomet, overseeing significant revenue growth from $1.2 billion to $7.7 billion. Berk brings over 30 years of oncology expertise and currently leads R&D at GT Biopharma. These appointments aim to enhance Beyond Cancer's strategic execution and expedite its ultra-high concentration nitric oxide therapy for solid tumors, with first human studies expected in the first half of this year.
Beyond Air, Inc. (NASDAQ: XAIR) will report its third fiscal quarter financial results, ending December 31, 2021, on February 10, 2022. A conference call is scheduled at 4:30 PM ET for management to discuss results and future developments. The company focuses on inhaled nitric oxide technology for treating respiratory diseases and is progressing its LungFit® system for clinical trials targeting severe lung infections, including COVID-19. For further details, visit www.beyondair.net.
Beyond Air (NASDAQ: XAIR) announced a delay in the U.S. commercial launch of LungFit® PH for persistent pulmonary hypertension of the newborn (PPHN), which will not occur before December 31, 2021. The company anticipates receiving CE Mark approval in Europe for LungFit® PH within the first half of 2022. Beyond Air is committed to advancing its nitric oxide delivery system for treating serious respiratory conditions and solid tumors, showcasing its dedication to regulatory collaboration and innovation in pediatric care.
Beyond Air (NASDAQ: XAIR) has appointed Dr. Andrew Colin as Chief Medical Officer effective December 1, 2021. Dr. Colin, with four decades in pediatric pulmonology, has been a key member of Beyond Air’s Scientific Advisory Board since 2013. His extensive experience includes over 20 clinical trials and contributions to various pulmonology advancements. The company is focused on developing inhaled nitric oxide therapies for respiratory conditions and solid tumors. The leadership change is expected to enhance the growth of clinical programs, particularly in acute viral infections and nontuberculous mycobacteria.